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Supplementary Figures  
 
Supplementary Figure 1. Nuclear PRDM14 expression in human gonadal PGCs. (A-D) IF images of PRDM14 
staining in human male and female gonadal sections of indicated stages (representative of 3 female and 2 male gonads). In 
A-C, hPGCs were marked by OCT4 (nuclear) and VASA (cytoplasmic) expression; in D, hPGCs are marked with OCT4 
(nuclear) expression. Nuclei were counterstained by DAPI. Scale bar is 100 µm (A-C) or 60 µm (D). (Supplementary Fig.1 
is continued on the next page)  
 
Supplementary Figure 1 (continued). Nuclear PRDM14 expression in human gonadal PGCs. (E) IF on sorted AP+ 
hESCs and AP+cKIT+ gonadal hPGCs. hPGCs and pluripotent hESCs were marked by OCT4. Nuclei were counterstained 
by DAPI. AP-cKIT- population (gonadal soma) was used as a negative control. Representative of 2 experiments (similar 
results were obtained for a Wk9 male embryo). Scale bar is 100 μm. 
 
 
Supplementary Figure 2. Expression dynamics of PRDM14-Venus and other germ cell and pluripotency markers 
during hPGCLC specification. Time-course IF analysis showing indicated proteins’ expression in embryoid body (EB) 
sections throughout hPGCLC specification from PRDM14-AID-Venus fusion reporter cell line. hPGCLCs were induced 
by cytokines (unless otherwise specified) and EBs were collected at 12hrs, and on D1-D5. Representative images for all 
timepoints are shown. Nuclei were counterstained by DAPI. Scale bar is 100 μm. (A) Time-course IF showing SOX17, 
PRDM14-Venus and OCT4 expression (representative of 2 experiments). Dashed line highlights SOX17+ cells. 





Supplementary Figure 2 (continued). Expression dynamics of PRDM14-Venus and other germ cell and pluripotency 
markers during hPGCLC specification. (B) Time-course IF showing BLIMP1, PRDM14-Venus and OCT4 expression 
(representative of 2 experiments). Dashed line highlights BLIMP1+ cells. (C) Quantification of results from (B) showing 
the percentage of PRDM14-Venus+BLIMP1+ cells as mean+/-SD of n=3 EB sections from 1 hPGCLC induction. (D) 
Quantification of results from (B) showing the percentage of PRDM14-Venus+BLIMP1+OCT4+ cells as mean+/-SD of n=3 
EB sections from 1 hPGCLC induction. (Supplementary Fig2 is continued on the next page) 
 
Supplementary Figure 2 (continued). Expression dynamics of PRDM14-Venus and other germ cell and pluripotency 
markers during hPGCLC specification. (E) Time-course IF showing TFAP2C, PRDM14-Venus and SOX2 expression 
in embryoid body (EB) sections throughout differentiation of PRDM14-AID-Venus cells without hPGCLC-inducing 
cytokines (representative of 1 experiment). Note that unlike normal induction with cytokines (Supplementary Figure 2F), 
“no cytokine” differentiation in the basal medium yields no hPGCLCs, but allows sustained SOX2 and PRDM14 
expression. (Supplementary Fig.2 is continued on the next page) 
 
Supplementary Figure 2 (continued). Expression dynamics of PRDM14-Venus and other germ cell and pluripotency 
markers during hPGCLC specification. (F) Time-course IF showing TFAP2C, PRDM14-Venus and SOX2 expression 
in embryoid body (EB) sections throughout differentiation of PRDM14-AID-Venus cells with hPGCLC-inducing 
cytokines (representative of 1 experiment). (Supplementary Fig.2 is continued on the next page) 
 
Supplementary Figure 2 (continued). Expression dynamics of PRDM14-Venus and other germ cell and pluripotency 
markers during hPGCLC specification. (G) Time-course IF showing SOX17, PRDM14-Venus and KLF4 expression 




Supplementary Figure 3. Selection of JAZ degron sequence and its validation in hESCs. (A) GFP depletion in HEK-
293T cells by three indicated JAZ degron versions. GFP fluorescence intensity was measured by flow cytometry after 
indicated times of Cor or DMSO (control) treatment. Data is from n=1 (for Cor 2h) or n=2 DMSO, Cor 4h and Cor 24h) 
independent experiments and is shown as relative geometric mean fluorescence intensity (normalised to DMSO control). 
(B) Scheme of the construct used to express GFP-JAZ in hESCs. COI1B (coronatine receptor) from rice (Oryza sativa) 
was fused to the F-box domain of TIR1 (Fb-TIR1). GFP fluorescent protein was fused to the JAZ degron. P2A and T2A – 
self-cleaving peptides. NLS – nuclear localisation signal. Puro – puromycin resistance gene. (C) Epifluorescence and 
bright-field photographs of GFP-JAZ hESCs after 3 hours or 1 day of Cor treatment (representative of 2 experiments). 
DMSO was used as a negative control for GFP depletion. Scale bar is 100 μm. (D) Flow cytometry plots confirming GFP-
JAZ depletion after one passage in the presence of Cor.  
 
 
Supplementary Figure 4. Venus fluorescence quantification shows higher efficiency of AID compared to JAZ 
degron. (A) Related to Fig.3B. Mean fluorescence intensities (MFI) of PRDM14-AID-Venus cells and indicated controls 
grown with or without IAA for 1 day. To focus on pluripotent cells that would normally express PRDM14, fluorescence 
intensities were measured in the nuclei of NANOG-positive cells. A cell line lacking TIR1 hormone receptor (“no TIR1”) 
was used as a negative control for PRDM14-AID-Venus depletion. Data show the mean n=3 (for PRDM14-AID-Venus) 
or n=1 (for “no TIR1”) experiments +/- SD using >100 NANOG+ cells per condition per replicate, **** P<0.0001 (two-
way ANOVA followed by Sidak’s multiple comparison test). (B) Related to Fig.3C. PRDM14-JAZ-Venus cells were 
grown with or without Cor for 1 days. To focus on pluripotent cells that would normally express PRDM14, fluorescence 
intensities were measured in the nuclei of OCT4-positive cells. A cell line lacking COI1B hormone receptor (“no COI1B”) 
was used as a negative control for PRDM14-JAZ-Venus depletion. Data show mean of >100 OCT4+ cells per condition 
from n=1 biological replicate. (C) Data from (A) normalised to a control cell line lacking AID-Venus KI. Data show the 
mean n=3 (for PRDM14-AID-Venus) or n=1 (for “no Venus”) experiments +/- SD using >100 NANOG+ cells per condition 
per replicate, **** P<0.0001 (two-way ANOVA followed by Sidak’s multiple comparison test). (D) Data from (B) 
normalised to a control cell line lacking JAZ-Venus KI. Data show mean of >100 OCT4+ cells per condition from n=1 
biological replicate. (E) Kinetics of Venus fluorescence depletion in PRDM14-AID-Venus hESCs. hESCs were treated 
with IAA for indicated time periods. Homogeneous depletion with Venus intensity close to “no Venus control” was reached 
within 25 minutes, as indicated by IF staining in Fig.3B. Data show mean of >100 cells per condition from n=1 biological 
replicate. (F) Kinetics of Venus fluorescence restoration in PRDM14-AID-Venus hESCs. hESCs were treated with IAA 
for 2 days, washed and grown without IAA for indicated periods of time. Data show mean of >100 cells per condition from 
n=1 biological replicate. 
 
 
Supplementary Figure 5. AID system allows studying the roles of PRDM14 and SOX17 TFs in cell fate decisions. 
(A) IF analysis of PRDM14-AID-Venus depletion in D4 IAA-treated EBs (representative of 2 experiments). SOX17 marks 
hPGCLCs. Scale bar is 60 μm. (B) Representative flow plots showing Venus fluorescence in AP+CD38+ hPGCLCs induced 
with or without auxin. (C) hPGCLC induction efficiencies from PRDM14-AID-Venus differentiated with or without         
500 µM IAA concentrations (note a different concentration compared to Fig.4B). The induction efficiency of untreated 
cells (“no IAA”) was set to 1. Data show mean+/-SD for n=5 for N3, cl8 and cl11; n=3 for “no TIR1” and cl21; ns – not 
significant: P=0.1322 for “no Venus” and P=0.4129 for “no TIR1”, **** P<0.0001 (Two-way ANOVA followed by 
Sidak’s multiple comparison test). (D) PRDM14 depletion using AID in H9 hESC background also reduces hPGCLC 
specification. Note that this cell line lacks NANOS3-tdTomato reporter and hPGCLCs were identified by AP and CD38 
staining. H9TIR10 is a parental cell line expressing TIR1 but lacking the AID-Venus KI. Data show mean+/-SD for n=3 
independent experiments per clone, ** P=0.0028, **** P<0.0001 (Two-way ANOVA followed by Sidak’s multiple 
comparison test). (E) Epifluorescence photographs show colocalization of NANOS3-tdTomato and SOX17-AID-Venus 
fluorescence in D4 EBs; both signals are reduced upon IAA treatment. Representative of 3 experiments. Scale bar is              
100 μm. (F) Representative flow cytometry plots showing hPGCLC induction using the SOX17-AID-Venus cell line with 
or without IAA. (G) SOX17 degradation decreases definitive endoderm (DE) specification. Representative flow cytometry 
plots; DE cells are marked by CXCR4 expression. (H) Experimental workflow of PRDM14 depletion in competent hESCs, 
as well as during preME induction. PRDM14 role in competence maintenance was assessed by depleting it in competent 
(4i) hESCs, followed by washing off the IAA for PRDM14 restoration and inducing hPGCLCs (without IAA). To test if 
PRDM14 is required for competence acquisition, it was depleted during the generation of the preME competent cells. 
Auxin was subsequently removed and hPGCLCs were induced without IAA. (I) PRDM14-AID depletion in competent 
hESCs does not reduce hPGCLC induction therefrom. IAA was added for 1 passage (3 days) prior to hPGCLC induction 
and washed of before the onset of hPGCLC differentiation. hESCs grown without auxin were differentiated with or without 
IAA as above. Data show mean+/-SD for n=2 (no TIR1 control) and n=4 (PRDM14-AID) independent experiments,           
**** P<0.0001 (Two-way ANOVA followed by Sidak’s multiple comparison test). (J) PRDM14-AID depletion during 
the acquisition of hPGC-competent state via pre-mesendoderm (preME) does not reduce hPGCLC induction therefrom. 
IAA was added for 12 hours during preME generation from conventional hESCs and washed off before the onset of 
hPGCLC differentiation. preME induced without auxin was differentiated with or without IAA as above. Data show mean 





Supplementary Figure 6. Transcriptional changes in hPGCLCs induced without PRDM14. (A) Heatmap showing 
Pearson’s correlation between hPGCLC RNA-seq samples. “Par” denotes parental control lacking TIR1 and hence 
unresponsive to auxin; “r” – Pearson’s correlation coefficient. PRDM14-depleting clones cluster separately and are 
highlighted in red. (B) Gene set enrichment analysis (GSEA) of 123 hPGC-specific genes on the transcriptome of 
hPGCLCs specified with or without IAA. PRDM14-deficient hPGCLCs (“PGCLC+IAA”) are negatively correlated with 
the gene set, if compared against “PGCLC no IAA” control. (C) qPCR shows transcriptional rescue of tested DEGs by 
ectopic PRDM14-DD. hPGCLCs were differentiated with or without IAA and/or Shield-1 (Sh) and sorted as NANOS3-
tdTomato+AP+ cells; soma denotes the double-negative population from the same experiments. Data show gene expression 
relative to no IAA no Sh PGCLCs and normalised to GAPDH, mean of n=2 independent experiments. (D) Parental (“no 
TIR1”) control for qPCR validation of RNA-seq (see Fig.6G). hPGCLCs were sorted as NANOS3-tdTomato+AP+ cells, 
while soma denotes the double-negative population from the same experiments. Data show gene expression relative to no 
IAA hPGCLCs and normalised to GAPDH, mean+/-SEM of n=4 (SOX17, NANOG, VENTX) mean +/-SEM of n=3 
(BLIMP1, TFAP2C, KLF4), mean of n=2 (NANOS3) or from of n=1 (other genes) independent experiments, all not 
significant by multiple unpaired t-tests (two-tailed P>0.18). (E) qPCR on unsorted PGC-competent (4i) PRDM14-AID 
hESCs cultured with or without IAA for 3 consecutive passages. The parental cell line lacking TIR1 is shown as a control. 
Data show mean of n=2 hormone-sensitive clones; n=1 for the parental control. Note downregulation of pluripotency genes 
and upregulation of pro-neuronal differentiation transcripts. (F) Venn diagrams highlighting significant overlap between 
transcriptional changes in hPGCLCs lacking PRDM14, TFAP2C or BLIMP1 (relative to corresponding WT controls). P-
values were obtained using a modified hypergeometric test (Polanski et al., 2014). (G) GO analysis performed on shared 
upregulated genes. The graph shows top non-redundant GO terms as –log10(p-value). (H) Co-expression network of 
differentially expressed genes in hPGCLCs (+IAA vs no IAA, log2FC > 1.5,  p-value < 0.05). Nodes were scaled according 
to the number of PRDM14 ChIP-seq peaks assigned to the gene. The network was partitioned into overlapping communities 
using the Louvain method (see Methods). Representative direct targets of PRDM14 were labelled. Upregulated genes were 




Supplementary Figure 7. PRDM14-Venus ChIP optimisation and GO analysis on direct targets of PRDM14.              
(A) ChIP-qPCR in competent PRDM14-AID-Venus hESCs using different antibodies. Anti-GFP antibody allows higher 
enrichment than the tested anti-PRDM14 antibodies. The primers were designed to span selected PRDM14 ChIP-seq peaks 
in conventional hESCs from (Chia et al. 2010). Data show log10 enrichment normalised to input and relative to a gene 
desert region (control), mean+/-SEM for n=1 (GFP+IAA, PRDM14 ABD4350 +IAA, PRDM14 ABD121 no IAA, 
PRDM14 ABD121 +IAA), n=2 (PRDM14 ABD4350 no IAA), n=3 (GFP no IAA) independent experiments. (B) GO 
analysis on hPGCLC-specific PRDM14 peaks (q-value<0.05) near genes upregulated in hPGCLCs upon PRDM14 
depletion. Top non-redundant GO terms are shown as –log10(p-value).  
 
Supplementary Figure 8. Comparison of molecular functions of PRDM14 in mouse and human PGCLCs. (A) Venn 
diagrams comparing transcriptional changes in Prdm14-/- mouse PGCLCs and PRDM14-AID hPGCLCs (+IAA) relative 
to corresponding WT controls. P-values were obtained by pairwise hypergeometric tests. Examples of overlapping DEGs 
are shown. * In PRDM14-AID hPGCLCs PRDM14 is depleted only at the protein level, while the transcript is still present 
and even upregulated, presumably due to autoregulation. (B) 3D PCA plot showing distinct transcriptional response of 
mouse and human PGCLCs to the absence of PRDM14. Data from Supplementary Data 4 with logFC>1 were used. Note 
that mouse WT and KO samples separate by PC4, while human samples induced with or without PRDM14 separate along 
PC3. Par – parental control lacking TIR1; r1 and r2 – replicates 1 and 2. (C) IF analysis of UHRF1 expression in D4 
PRDM14-AID EBs induced in the presence of auxin (representative of 2 experiments). hPGCLCs are marked by OCT4, 
proliferating cells are marked by Ki-67. OCT4-positive cells are highlighted by a dashed line. White arrows show examples 
of PRDM14-deficient proliferating hPGCLC that retain UHRF1. Scale bar is 100 μm. (D) IF analysis of H3K9me2 levels 
in D4 PRDM14-AID EBs (representative of 1 experiment). hPGCLCs are marked by OCT4, proliferating cells are marked 
by Ki-67. OCT4-positive cells are highlighted by a dashed line. Scale bar is 100 μm. (E) UHRF1 MFI in D4 EBs. 
Proliferating hPGCLCs were identified as OCT4+Ki67+ cells. Note that UHRF1 fluorescence intensities in hPGCLCs+IAA 
and soma+IAA were normalised by the ratio of median fluorescence in “soma+IAA” to “soma no IAA”. The box and 
whisker plots show MFI of n>20 cells per condition (see (G)) from n=1 staining. The cross (x) in the box shows the mean, 
while the line shows the median of the dataset. The distance from the bottom to the upper line of the box shows the 
interquartile range (IQR). Quartiles were calculated using the exclusive median method. The whiskers show +/- 1.5×IQR 
with any data points below or above the whiskers considered as outliers. (F) H3K9me2 MFI in D4 EBs. Proliferating 
hPGCLCs were identified as OCT4+Ki67+ cells. Note that H3K9me2 fluorescence intensities in hPGCLCs+IAA and 
soma+IAA were normalised by the ratio of median fluorescence in “soma+IAA” to “soma no IAA”. The box and whisker 
plots show MFI of n>10 cells per condition (see (H)) from n=1 staining. The cross (x) in the box shows the mean, while 
the line shows the median of the dataset. The distance from the bottom to the upper line of the box shows the interquartile 
range (IQR). Quartiles were calculated using the exclusive median method. The whiskers show +/- 1.5×IQR with any data 
points below or above the whiskers considered as outliers. (G) Quantification of UHRF1-positive cells in proliferating 
hPGCLCs and soma of PRDM14-AID and control EBs. Normalised fluorescence values were used. Numbers of UHRF1 
positive and total cells counted are shown for each sample. (H) Quantification of H3K9me2-positive cells in proliferating 
hPGCLCs and soma of PRDM14-AID EBs. Normalised fluorescence values were used. Numbers of H3K9me2 positive 
and total cells counted are shown for each sample. (I) Representative (of 3 experiments) flow cytometry plots showing that 
ectopic PRDM14 induced by either dox or Shield-1 does not induce hPGCLC induction without BMP2 and other cytokines 









Supplementary Figure 9. Graphical summary of key findings. Model summarising the context-dependent PRDM14 
roles in human pluripotency and hPGCLC specification. Using PRDM14-AID-Venus we were able to map PRDM14 
binding in hESCs and hPGCLCs, as well as deplete the protein with high time resolution. This showed that PRDM14 
regulates target genes through promoter binding together with SOX2/OCT4 in hESCs or TFAP2C and BLIMP1 in 
hPGCLCs. PRDM14, TFAP2C and BLIMP1 are all downstream of SOX17. In hESCs, PRDM14 activates the expression 
of pluripotency genes and represses pro-differentiation genes. Similarly, in hPGCLCs, PRDM14 represses somatic 
transcripts, but activates germ cell- and pluripotency-related genes. Representative examples of activated and repressed 
genes are shown. When auxin is added PRDM14-AID fusion protein is recruited to the E3 ubiquitin ligase via an F-box 
auxin receptor TIR1. It leads to rapid protein ubiquitination and degradation, which allows time-resolved functional studies.  
 
Supplementary Figure 10. Flow cytometry and FACS gating strategy to identify hPGCLCs. The gating was 
performed as follows: the initial cell population was defined as the largest compact events cluster on the SSC-A vs FSC-A 
plot; then cell doublets were eliminated using FSC-A vs FSC-H plot; afterwards dead cells were eliminated based on DAPI-
positivity; finally, gating on live (DAPI-negative) cells, hPGCLCs were defined as NANOS3-tdTomato+AP+ (or NANOS3-
tdTomato+CD38+) cells. The boundaries between positive and negative gates were defined using unstained samples and 














Supplementary Tables  
Supplementary Table 1. Mesendoderm (ME) medium composition. 
Component Final Concentration Supplier 
Advanced RPMI 1640  - GIBCO 
B27 supplement  1% GIBCO 
L-glutamine 2 mM GIBCO 
Nonessential amino acids 0.1 mM GIBCO 
Penicillin-Streptomycin 
100 U/ml (Penicillin) 
GIBCO 
0.1 mg/ml (Streptomycin) 
Activin A 100 ng/ml SCI 
CHIR99021 3 μM Miltenyi Biotec 
ROCK inhibitor (Y-27632)  10 μM TOCRIS bioscience 
Supplementary Table 2. Definitive endoderm (DE) medium composition. 
Component Final Concentration Supplier 
Advanced RPMI 1640  - GIBCO 
B27 supplement  1% GIBCO 
L-glutamine 2 mM GIBCO 
Nonessential amino acids 0.1 mM GIBCO 
Penicillin-Streptomycin 
100 U/ml (Penicillin) 
GIBCO 
0.1 mg/ml (Streptomycin) 
Activin A 100 ng/ml SCI 
BMP inhibitor (LDN193189)  0.5 μM Sigma 





























Supplementary Table 3. Antibodies used in the study. 





cytometry 0.5 μl/6 EBs  
BD 
Pharmingen 
Irie N et al. 20151: FACS purification of 





cytometry 0.5 μl/6 EBs 
BD 
Pharmingen 
Irie N et al. 20151: FACS purification of 




cytometry 0.5 μl/6 EBs BioLegend 
Irie N et al. 20151: FACS purification of 




cytometry 0.5 μl/6 EBs BioLegend 
Irie N et al. 20151: FACS purification of 





















Tang WW et al. 20152: FACS purification of 
human PGCs 
PRDM14 AB4350 ChIP and IF  
1:100 for IF; 




IF: Irie N et al. 20151: IF on human PGCLCs; 
ChIP: antibody was validated in this 
manuscript by ChIP qPCR on PRDM14-
target and control regions (Chia et al. 20103) 
in wild type and PRDM14-depleted hESCs 
(Supplementary Fig.7a). 
OCT4 #611203 IF 1:200 BD Biosciences Tang WW et al. 2015
2: IF on human PGCs 
SOX17 AF1924 IF 1:500 R&D Systems Tang WW et al. 20152: IF on human PGCs 
GFP ab13970 IF 1:1000 Abcam Manufacturer validated by IF on GFP-transfected NIH/3T3 cells 
PRDM14 ABD121 ChIP   3 μl / 2.5 million cells  Millipore 
Antibody was validated in this manuscript by 
ChIP qPCR on PRDM14-target and control 
regions (Chia et al. 20103) in wild type and 
PRDM14 depleted hESCs (Supplementary 
Fig.7A). 
GFP ab290 ChIP   0.5 μl / 2.5 million cells  Abcam 
Antibody was validated in this manuscript by 
ChIP qPCR on PRDM14-target and control 
regions (Chia et al. 20103) in wild type and 
PRDM14 depleted hESCs (Supplementary 
Fig.7A). 
TFAP2C sc-8977 IF 1:100 Santa Cruz Tang WW et al. 20152: IF on human PGCs 
BLIMP1 #14-5963 IF 1:50 eBioscience Tang WW et al. 20152: IF on human PGCs 
SOX2 sc-17320 IF 1:200 Santa Cruz Irie N et al. 20151: IF on human PGCLCs  
myc-tag #2276 IF 1:4000 CST Manufacturer validated by IF on COS cells transfected with a myc-tagged protein  
HA-tag #3724 IF 1:200 CST Manufacturer validated by IF on COS cells, transfected with an HA-tagged protein  
V5-tag ab27671 IF 1:100 Abcam Manufacturer validated by IF on CHO cells overexpressing a V5-tagged protein 
Ki-67 ab16667 IF 1:500 Abcam Irie N et al. 20151: IF on human PGCLCs  
NANOG ab80892 IF 1:100 Abcam Manufacturer validated by IF on mES cells 
UHRF1 #61342 IF 1:500 Active Motif Tang WW et al. 20152: IF on human PGCs 
Alexa fluorophore 
(AF-488, 568 and/or 
647)-conjugated 
secondary antibodies  
IF 1:500 Invitrogen (ThermoFisher) 
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